Replies to post #401502 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

If your view were the reality of GBM, the average life expectancy would be many times higher than it is generally, and that is not the case. Moreover, we know the IDH context for many patients and they are not the better prognosis patients at all, both because of biomarkers but also because of the size of their tumors. It is perverse that negative predictors claim a huge brain tumor is a positive prognosis for a long life after surgery and then they ignore the additional factors that are negative, and make spurious claims about other factors. And in some cases, the same posters will not analyze other trials that the promote, in the same basis.

[Dr Bala]

LL's statements are the only ones that count.

[learningcurve2020]

Assuming the 2018 interim data wasn't totally manipulated / misinterpreted bs, then they are obviously wrestling with the data, unable to convince regulators of efficacy. In other words, the tld is in limbo maybe forever or until a technology comes along to drill down further on bio markers in LTS to resolve the confounding issues.

This is an interesting chat by the Dana folks. Note the emphases on funding. Appears to further trials they're choosing philanthropy rather than get mixed up with a public company.